Gene expression profiling and clinical outcome in melanoma: in search of novel prognostic factors

References

• Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst.94(12), 894–903 (2002).
   PubMed Web of Science ®Google Scholar
• Wachsmuth RC, Harland M, Bishop JA. The atypical-mole syndrome and predisposition to melanoma. N. Engl. J. Med.339(5), 348–349 (1998).
   Google Scholar
• Lew RA, Sober AJ, Cook N, Marvell R, Fitzpatrick TB. Sun exposure habits in patients with cutaneous melanoma – a case control study. J. Dermatol. Surg. Oncol.9(12), 981–986 (1983).
   Google Scholar
• Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene22(20), 3099–3112 (2003).
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry D, Epstein MN, Greene MH, Van HM. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol.15(12), 1147–1165 (1984).
   PubMed Web of Science ®Google Scholar
• Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol.19(16), 3622–3634 (2001).
   PubMed Web of Science ®Google Scholar
• Clark WH Jr, Elder DE, Guerry D et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst.81(24), 1893–1904 (1989).
   PubMed Web of Science ®Google Scholar
• Balch CM, Sober AJ, Soong SJ, Gershenwald JE. The new melanoma staging system. Semin. Cutan. Med. Surg.22(1), 42–54 (2003).
   Google Scholar
• Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol.38(5), 535–547 (1999).
   Web of Science ®Google Scholar
• Spatz A, Gimotty PA, Cook MG et al. Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: an EORTC Melanoma Group study. J. Clin. Oncol.25(Suppl. 18), 8519 (2007).
   Google Scholar
• Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch. Pathol. Lab. Med.125(10), 1295–1306 (2001).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Michaelsen J, Brenner W et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res.9(2), 155–161 (1999).
   Google Scholar
• Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res.20(3B), 2203–2206 (2000).
   PubMed Web of Science ®Google Scholar
• Banfalvi T, Gilde K, Boldizsar M et al. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur. J. Clin. Invest.30(10), 900–904 (2000).
   PubMedGoogle Scholar
• Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and HS interleukin-10 serum levels in patients with melanoma. Br. J. Cancer83(7), 847–852 (2000).
   PubMed Web of Science ®Google Scholar
• Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res.60(8), 2253–2257 (2000).
   PubMed Web of Science ®Google Scholar
• Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J. Am. Acad. Dermatol.44(2), 188–192 (2001).
   Google Scholar
• Gimotty PA, Van BP, Elder DE et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J. Clin. Oncol.23(31), 8048–8056 (2005).
   PubMed Web of Science ®Google Scholar
• Kesmodel SB, Karakousis GC, Botbyl JD et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann. Surg. Oncol.12(6), 449–458 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev.18(3), 345–357 (1999).
   PubMed Web of Science ®Google Scholar
• Ranuncolo SM, Ladeda V, Gorostidy S et al. Expression of CD44s and CD44 splice variants in human melanoma. Oncol. Rep.9(1), 51–56 (2002).
   Google Scholar
• Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray. Int. J. Cancer118(6), 1460–1464 (2006).
   Google Scholar
• Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilsson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast. Reconstr. Surg.115(2), 367–375 (2005).
   Google Scholar
• Natali P, Nicotra MR, Cavaliere R et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res.50(4), 1271–1278 (1990).
   PubMed Web of Science ®Google Scholar
• Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res.61(9), 3819–3825 (2001).
   PubMed Web of Science ®Google Scholar
• Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumors. Mol. Pathol.52(3), 151–157 (1999).
   PubMedGoogle Scholar
• Ferrier CM, Suciu S, van Geloof WL et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br. J. Cancer83(10), 1351–1359 (2000).
   Google Scholar
• Vaisanen A, Kallioinen M, von Dickhoff K, Laatikainen L, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein – a new prognostic marker in uveal melanoma? J. Pathol.188(1), 56–62 (1999).
   PubMedGoogle Scholar
• van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am. J. Pathol.151(3), 665–670 (1997).
   PubMed Web of Science ®Google Scholar
• Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G. Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer91(5), 972–982 (2001).
   PubMedGoogle Scholar
• van den Oord JJ, Vandeghinste N, De Ley M, de Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am. J. Pathol.145(2), 294–300 (1994).
   Google Scholar
• Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol.22(4), 347–349 (1996).
   Google Scholar
• Gradilone A, Gazzaniga P, Ribuffo D et al. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol.21(2), 306–312 (2003).
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res.60(17), 4932–4938 (2000).
   Google Scholar
• Barnhill RL, Busam KJ, Berwick M et al. Tumor vascularity is not a prognostic factor for cutaneous melanoma. Lancet344(8931), 1237–1238 (1994).
   Google Scholar
• Dadras SS, Lange-Asschenfeldt B, Velasco P et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod. Pathol.18(9), 1232–1242 (2005).
   PubMed Web of Science ®Google Scholar
• Salti GI, Manougian T, Farolan M et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res.60(18), 5012–5016 (2000).
   Google Scholar
• van den Oord JJ, Maes A, Stas M et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol.149(6), 1953–1961 (1996).
   PubMed Web of Science ®Google Scholar
• Demunter A, Ahmadian MR, Libbrecht L et al. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res.61(12), 4916–4922 (2001).
   Google Scholar
• Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Lett.214(2), 133–147 (2004).
   Google Scholar
• Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene22(58), 9217–9224 (2003).
   PubMedGoogle Scholar
• Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R et al. Constitutive activation of the Ras–Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog.3(1), 6 (2004).
   Google Scholar
• Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res..10(5), 1753–1757 (2004).
   PubMed Web of Science ®Google Scholar
• Ross DA, Wilson GD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br. J. Surg.85(1), 46–51 (1998).
   PubMed Web of Science ®Google Scholar
• Hussein MR, Haemel AK, Wood GS. p53-related pathways and the molecular pathogenesis of melanoma. Eur. J. Cancer Prev.12(2), 93–100 (2003).
   PubMed Web of Science ®Google Scholar
• Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for Rho-C. Nature406(6795), 532–535 (2000).
   PubMed Web of Science ®Google Scholar
• Carr KM, Bittner M, Trent JM. Gene-expression profiling in human cutaneous melanoma. Oncogene22(20), 3076–3080 (2003).
   PubMed Web of Science ®Google Scholar
• de Wit NJ, Rijntjes J, Diepstra JH et al. Analysis of differential gene expression in human melanocytic tumor lesions by custom made oligonucleotide arrays. Br. J. Cancer92(12), 2249–2261 (2005).
   PubMedGoogle Scholar
• Baldi A, Battista T, De Luca A et al. Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp. Dermatol.12(2), 213–218 (2003).
   PubMed Web of Science ®Google Scholar
• Brem R, Hildebrandt T, Jarsch M, van Muijen GN, Weidle UH. Identification of metastasis-associated genes by transcriptional profiling of a metastasizing versus a non-metastasizing human melanoma cell line. Anticancer Res.21(3B), 1731–1740 (2001).
   PubMed Web of Science ®Google Scholar
• Hoek K, Rimm DL, Williams KR et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res.64(15), 5270–5282 (2004).
   PubMed Web of Science ®Google Scholar
• Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature406(6795), 536–540 (2000).
   PubMed Web of Science ®Google Scholar
• Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res.62(13), 3581–3586 (2002).
   PubMed Web of Science ®Google Scholar
• Winnepenninckx V, Lazar V, Michiels S et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst.98, 472–482 (2006)
   PubMedGoogle Scholar
• Kaufmann WK, Nevis KR, Qu P et al. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J. Invest. Dermatol. (2007) (Epub ahead of print).
   Google Scholar
• Blagosklonny MV, An WG, Melillo G, Nguyen P, Trepel JB, Neckers LM. Regulation of BRCA1 by protein degradation. Oncogene18, 6460–6468 (1999).
   PubMedGoogle Scholar
• Mukherjee G, Muralidhar B, Bafna UD, Laskey RA, Coleman N. MCM immunocytochemistry as a first line cervical screening test in developing countries: a prospective cohort study in a regional cancer centre in India. Br. J. Cancer96, 1107–1111 (2007).
   PubMed Web of Science ®Google Scholar
• Lee C, Hong B, Choi JM et al. Structural basis for inhibition of the replication licensing factor Cdt1 by geminin. Nature430, 913–917 (2004).
   PubMed Web of Science ®Google Scholar
• Gonzalez MA, Tachibana KE, Laskey RA, Coleman N. Control of DNA replication and its potential clinical exploitation. Nat. Rev. Cancer5, 135–141 (2005).
   PubMed Web of Science ®Google Scholar
• De Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett.230, 153–186 (2005).
   PubMedGoogle Scholar
• Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene23, 4014–4022 (2004).
   PubMed Web of Science ®Google Scholar
• Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijama T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res.66, 6080–6086 (2006).
   Google Scholar
• Fargeas CA, Florek M, Huttner WB, Corbeil D. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J. Biol. Chem.278, 8586–8596 (2003).
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate64, 67–74 (2005).
   PubMed Web of Science ®Google Scholar
• Su B, Guan M, Xia J, Lu Y. Stimulation of lipocalin-type prostaglandin D synthase by retinoic acid coincides with inhibition of cell proliferation in human 3AO ovarian cancer cells. Cell Biol. Int.27, 587–592 (2003).
   Google Scholar
• Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer6, 735–741 (2006).
   PubMed Web of Science ®Google Scholar
• Collisson EA, Kleer C, Wu M et al. Atorvastatin prevents Rho-C isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther.2, 941–948 (2003).
   PubMed Web of Science ®Google Scholar
• Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene23, 39–48 (2004).
   PubMed Web of Science ®Google Scholar
• Pennati M, Binda M, De Cesare M et al. Ribozyme-mediated downregulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis25, 1129–1136 (2004).
   PubMedGoogle Scholar
• Zhu ZB, Makhija SK, Lu B et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther.11, 256–262 (2004).
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res.24, 2783–2784 (2004).
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med.353, 2135–2147 (2005).
   PubMed Web of Science ®Google Scholar
• Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43–9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res.66, 1611–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Qin JZ, Ziffra J, Stennett L et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res.65, 6282–6293 (2005).
   PubMed Web of Science ®Google Scholar